226950.KQ

OliX Pharmaceuticals, Inc. is a biotechnology firm in the clinical development phase, specializing in the creation of RNA interference (RNAi) treatments. Its primary focus lies in developing therapies for various conditions affecting the skin (dermal), eyes (ophthalmic), and lungs (pulmonary). The company maintains a robust pipeline of experimental medicines, including: For dermatological applications: OLX101 (targeting skin scars), OLX102 (for skin whitening), OLX103 (an atopic dermatitis candidate), OLX104 (addressing hair loss), OLX105 (an anti-wrinkle product), and OLX106 (for diabetic foot ulcers). For ophthalmic disorders: OLX301 (for age-related macular degeneration retinal fibrosis) and OLX304 (for retinitis pigmentosa). For respiratory diseases: OLX201 (lung fibrosis), OLX202 (asthma), and OLX203 (influenza). Other significant programs encompass: OLX401 (neuropathic pain), OLX701 (liver fibrosis), and a distinct OLX701 designated for cancer immunotherapy. Furthermore, OliX Pharmaceuticals has forged strategic partnerships, including a collaborative agreement with Théa to advance SiRNA therapeutics for eye-related diseases, and a research alliance with PCI Biotech Holding ASA. Established in 2010, the company's operations are based in Suwon, South Korea.